<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385215</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00024277</org_study_id>
    <nct_id>NCT01385215</nct_id>
  </id_info>
  <brief_title>Strategies for Enhancing Mucosal Immunity to Influenza Vaccine</brief_title>
  <official_title>Strategies for Enhancing Mucosal Immunity to Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Sundy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of the influenza&#xD;
      vaccine when administered nasally and intra-muscular (a &quot;shot&quot; of medicine given into a&#xD;
      muscle). The investigators will measure the systemic (through out the body) and mucosal&#xD;
      immune responses (how your body recognizes and defends itself against bacteria) to nasally&#xD;
      administered influenza vaccine, and determine if nasal immunization results in immunity (your&#xD;
      body's ability to avoid infections) within multiple mucosal compartments (ocular (eye), oral&#xD;
      and reproductive), in comparison with intramuscular administration and placebo (inactive&#xD;
      substance given in the same form as the active drug).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hemagglutinin antibody titers from baseline to Day 28 in serum and mucosal secretions.</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Assessments will include hemagglutination inhibition and antibody isotypes determination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events.</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of hemagglutinin antibody titers between intranasal and intramuscular route of administration, from baseline to Day 28.</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Mucosal Immunity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal Aerosol Immunization</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal Droplet Immunization</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular Immunization</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzone</intervention_name>
    <description>0.5 ml/15 micrograms</description>
    <arm_group_label>Intramuscular Immunization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzone</intervention_name>
    <description>0.5 ml/60 micrograms</description>
    <arm_group_label>Nasal Aerosol Immunization</arm_group_label>
    <arm_group_label>Nasal Droplet Immunization</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women ages 18-50 years&#xD;
&#xD;
          -  Non-smokers (defined as no tobacco use within the last 12 months and less than 10&#xD;
             pack-year lifetime tobacco use)&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Able to speak and understand English&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Influenza vaccination within 6 months prior to screening date&#xD;
&#xD;
          -  Symptoms of respiratory infection during the 14 days prior to screening&#xD;
&#xD;
          -  Temperature &gt;38.3o C during the period spanning 72 hours prior to screening and the&#xD;
             time of immunization.&#xD;
&#xD;
          -  History of allergy to egg, influenza vaccine or vaccine ingredients&#xD;
&#xD;
          -  History of Guillain-Barre syndrome&#xD;
&#xD;
          -  History of Bell's palsy&#xD;
&#xD;
          -  Tonsillectomy, adenoidectomy or prior surgery to the paranasal sinus cavity.&#xD;
&#xD;
          -  Physician diagnosis of or personal history of allergic or chronic rhinitis&#xD;
&#xD;
          -  Physician diagnosis of or personal history of asthma&#xD;
&#xD;
          -  Acute sinusitis within 30 days prior to screening&#xD;
&#xD;
          -  Use of antibiotics within 14 days prior to screening&#xD;
&#xD;
          -  Requirement for use of nasal corticosteroids for the period beginning 30 days prior to&#xD;
             screening through final study visit&#xD;
&#xD;
          -  Requirement for use of antihistamines (systemic, intranasal or intraocular) for the&#xD;
             period beginning 72 hours prior to screening through final study visit&#xD;
&#xD;
          -  Use of immunomodulating drugs or systemic corticosteroids within 6 months prior to&#xD;
             screening (includes but is not limited to azathioprine, methotrexate, mycophenolate&#xD;
             mofetil, tumor necrosis factor inhibitors, cyclosporine, tacrolimus)&#xD;
&#xD;
          -  Past or present history of allergen immunotherapy to within the last 10 years.&#xD;
&#xD;
          -  Students or employees who are under direct supervision by any of the investigators in&#xD;
             this protocol are not eligible to participate.&#xD;
&#xD;
          -  Subjects who abuse alcohol or illicit substances will be excluded.&#xD;
&#xD;
          -  Other medical or psychological conditions which, in the opinion of the investigator,&#xD;
             might create undue risk to the subject or interfere with the subject's ability to&#xD;
             comply with the protocol requirements.&#xD;
&#xD;
          -  Nursing mothers.&#xD;
&#xD;
          -  Other investigational medication use within 30 days of screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Sundy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>April 25, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <last_update_submitted>December 5, 2012</last_update_submitted>
  <last_update_submitted_qc>December 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>John Sundy</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Mucosal Immunity</keyword>
  <keyword>Nasal Immunization</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

